Prevalence and Predictors of Persistent Symptoms After Clearance of SARS-CoV-2 Infection: A Multicenter Study from Egypt.
COVID-19
SARS-CoV-2
coronavirus
dyspnea
fatigue
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
12
2021
accepted:
12
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
Little is known about the persistence of symptoms after clearance of SARS-CoV-2 infection. Our study aimed to assess persistent symptoms in COVID-19 patients after clearance of SARS-CoV-2 infection. A multi-center survey was conducted on first wave COVID-19 patients with confirmed SARS-CoV-2 infection. Sociodemographic and clinical characteristics, including presenting symptoms and persistent symptoms after viral clearance and possible factors contributing to persistence of such symptoms, were collected using an online multicomponent questionnaire. Descriptive and inferential statistical analysis was performed to detect the most persisting symptoms and factors contributing to their persistence. Overall, 538 patients were enrolled. Mean age was 41.17 (±SD 14.84), 54.1% were males, and 18.6% were smokers. Hypertension and diabetes were the most reported co-morbidities. Mild symptoms were reported in 61.3% of patients, 51.3% were admitted to hospital and 6.5% were admitted to the intensive care unit. Our study identified 49 types of persisting symptoms. Fatigue (59.1%), sense of fever (46.5%), anorexia (24.3%) and diarrhea (24.3%) were the most commonly reported persisting symptoms followed by loss of taste and smell (22.3%), headache (21.4%), cough (20.8) and dyspnea (21%). The use of hydroxychloroquine, azithromycin and multivitamins were significantly associated with persistence of symptoms (OR = 8.03, 8.89 and 10.12, respectively). Our study revealed that in COVID-19 recovered patients, many patients reported persistence of at least one symptom, particularly fatigue and sense of fever. Follow-up of patients after discharge from hospital is recommended until complete resolution of symptoms.
Sections du résumé
Background and Aim
UNASSIGNED
Little is known about the persistence of symptoms after clearance of SARS-CoV-2 infection. Our study aimed to assess persistent symptoms in COVID-19 patients after clearance of SARS-CoV-2 infection.
Methodology
UNASSIGNED
A multi-center survey was conducted on first wave COVID-19 patients with confirmed SARS-CoV-2 infection. Sociodemographic and clinical characteristics, including presenting symptoms and persistent symptoms after viral clearance and possible factors contributing to persistence of such symptoms, were collected using an online multicomponent questionnaire. Descriptive and inferential statistical analysis was performed to detect the most persisting symptoms and factors contributing to their persistence.
Results
UNASSIGNED
Overall, 538 patients were enrolled. Mean age was 41.17 (±SD 14.84), 54.1% were males, and 18.6% were smokers. Hypertension and diabetes were the most reported co-morbidities. Mild symptoms were reported in 61.3% of patients, 51.3% were admitted to hospital and 6.5% were admitted to the intensive care unit. Our study identified 49 types of persisting symptoms. Fatigue (59.1%), sense of fever (46.5%), anorexia (24.3%) and diarrhea (24.3%) were the most commonly reported persisting symptoms followed by loss of taste and smell (22.3%), headache (21.4%), cough (20.8) and dyspnea (21%). The use of hydroxychloroquine, azithromycin and multivitamins were significantly associated with persistence of symptoms (OR = 8.03, 8.89 and 10.12, respectively).
Conclusion
UNASSIGNED
Our study revealed that in COVID-19 recovered patients, many patients reported persistence of at least one symptom, particularly fatigue and sense of fever. Follow-up of patients after discharge from hospital is recommended until complete resolution of symptoms.
Identifiants
pubmed: 35619736
doi: 10.2147/IDR.S355064
pii: 355064
pmc: PMC9128749
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2575-2587Informations de copyright
© 2022 Khalaf et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Br J Surg. 2021 Sep 27;108(9):1056-1063
pubmed: 33761533
Int J Infect Dis. 2020 Apr;93:297-299
pubmed: 32147538
JAMA Netw Open. 2020 Jun 1;3(6):e2011335
pubmed: 32525549
BMJ. 2020 Jun 3;369:m2094
pubmed: 32493739
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
J Immunol Res. 2020 Nov 19;2020:8893483
pubmed: 33274246
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Open Forum Infect Dis. 2020 Aug 24;7(9):ofaa375
pubmed: 32999893
Open Forum Infect Dis. 2021 Sep 09;8(10):ofab440
pubmed: 34631916
J Infect. 1989 Mar;18(2):143-50
pubmed: 2540242
J Drug Deliv Sci Technol. 2021 Jun;63:102435
pubmed: 33643448
Clin Microbiol Infect. 2020 Nov;26(11):1448-1449
pubmed: 32712242
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Life (Basel). 2021 Jul 23;11(8):
pubmed: 34440478
Nanomedicine (Lond). 2020 Sep;15(21):2085-2102
pubmed: 32723142
Eur Respir J. 2017 Jun 15;49(6):
pubmed: 28619956
Arch Intern Med. 2007 Jun 25;167(12):1312-20
pubmed: 17592106
Front Public Health. 2021 Jul 07;9:591982
pubmed: 34307267
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1402-1409.e1
pubmed: 33007514
Arch Intern Med. 2009 Dec 14;169(22):2142-7
pubmed: 20008700
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Soc Sci Med. 2021 Jan;268:113426
pubmed: 33199035
Acta Neurol Scand. 2020 Jul;142(1):14-22
pubmed: 32412088
Ir Med J. 2020 Jun 11;113(6):102
pubmed: 32816437
QJM. 2020 Sep 1;113(9):657-665
pubmed: 32442308
Brain. 2020 Oct 1;143(10):3089-3103
pubmed: 32645151
Int J Clin Pract. 2020 Nov;74(11):e13637
pubmed: 32750190
Psychiatry Res. 2022 Feb;308:114353
pubmed: 34968807
Biology (Basel). 2020 Sep 09;9(9):
pubmed: 32916925
JAMA. 2021 Jan 19;325(3):304-306
pubmed: 33315057
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Neurology. 2020 Aug 25;95(8):e1060-e1070
pubmed: 32482845
Nat Rev Endocrinol. 2011 Sep 27;8(1):22-32
pubmed: 21946893
Vaccines (Basel). 2020 Aug 06;8(3):
pubmed: 32781571
Cureus. 2020 Aug 18;12(8):e9846
pubmed: 32953353
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Patient Relat Outcome Meas. 2015 Jul 30;6:215-23
pubmed: 26257528
Infect Drug Resist. 2021 Mar 23;14:1169-1184
pubmed: 33790587
Can Respir J. 2020 Sep 19;2020:2045341
pubmed: 33005276
Life Sci. 2021 May 15;273:119117
pubmed: 33508293
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Trends Psychiatry Psychother. 2021 Dec 30;:
pubmed: 34967182
Radiography (Lond). 2021 May;27(2):682-687
pubmed: 33008761
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773
Clin Infect Dis. 2016 Feb 15;62(4):448-455
pubmed: 26565004
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238